BAY12-9566 inhibits angiogenesis and matrix metalloproteases. Developed by Bayer, it is undergoing phase III comparative trials in the USA for the treatment of non-small-cell lung, small-cell lung and pancreatic cancer (900 patients in each trial). The National Institute of Canada's Clinical Trials Group has initiated an international phase III trial for the treatment of patients with advanced ovarian cancer (n = 900) who have responded positively to 6 to 8 cycles of standard chemotherapy after surgery. The study's primary objective is to determine the drug's effectiveness in keeping patients in remission. The study will take place in Canada, Europe, South Africa and Israel.BAY12-9566 is also being investigated for the treatment of osteoarthritis. Development for this indication appears to be at the phase I stage in the US.